Acyzol (Capsules, Solution) Instructions for Use
ATC Code
V03AB (Antidotes)
Active Substance
Zinc bisvinylimidazole diacetate (Grouping name)
Clinical-Pharmacological Group
Antidote
Pharmacotherapeutic Group
Antidote
Pharmacological Action
Acyzol is a highly effective antidote against acute poisoning with lethal doses of carbon monoxide, as well as an effective antihypoxant in oxygen deficiency.
The administration of Acyzol to victims in mass casualty areas increases their chances of survival in severe forms of intoxication, accelerates the elimination of carbon monoxide, and contributes to the success of subsequent medical measures.
Acyzol is an original domestic drug that has no analogues abroad in terms of structure and action. There have been no medicinal or prophylactic agents used for carbon monoxide poisoning until now.
The use of Acyzol opens a fundamentally new way to combat anoxia by changing the affinity of hemoglobin for blood gases and increasing tolerance to high concentrations of carboxyhemoglobin.
Acyzol prevents the formation of carboxyhemoglobin by influencing the cooperative interaction of hemoglobin subunits, resulting in a decrease in the relative affinity of hemoglobin for carbon monoxide and an improvement in the oxygen-binding and gas-transport properties of blood.
Acyzol reduces the severity of intoxication in carbon monoxide poisoning according to the severity of metabolic acidosis and accelerates the elimination of carbon monoxide (CO) from the body.
The protective index of Acyzol with parenteral use is 1.40-1.45. Oral administration of Acyzol enhances the prophylactic and therapeutic effect against carbon monoxide, and the protective index increases to 1.6-1.8.
Acyzol reduces the body’s oxygen demand and promotes increased resistance to hypoxia in organs most sensitive to oxygen deficiency: the brain, myocardium, and liver.
Acyzol is a complex zinc-organic compound and replenishes zinc deficiency in the body.
Pharmacokinetics
When taken orally, it is rapidly absorbed from the gastrointestinal tract. Cmax after a dose of 120 mg is reached in 1-1.5 hours. T1/2 is 1-1.5 hours; trace amounts of the drug are recorded after 8-10 hours. It is mainly metabolized in the liver.
With intramuscular administration of Acyzol, Cmax is reached 20-30 minutes after administration of a 60 mg (1 ml) dose and remains in the plasma for 4-5 hours. T1/2 is 1-1.5 hours.
Indications
- Prophylactic agent in case of threat of poisoning;
- Therapeutic agent for poisoning of varying severity by carbon monoxide (CO) and other products of thermal oxidative degradation;
- For emergency medical care in emergencies when people are affected by carbon monoxide and combustion products of organic substances in the foci of large-scale disasters and chemical accidents; mine and mine rescue operations, various fires (at industrial sites, in forests), ailments caused by automobile exhausts (traffic controllers, traffic police workers) – areas of application of Acyzol.
As an antihypoxic agent, Acyzol can be used for many diseases accompanied by ischemia and hypoxia of internal organs: in therapeutic and surgical practice, in urology, gynecology, dermatology, as well as for the treatment of functional impotence.
Due to its antihypoxic and antioxidant action, Acyzol can find application in resuscitation, emergency therapy, and surgery for the correction of metabolic acidosis and protection of cell membranes from the effects of lipid peroxidation products.
Acyzol can be recommended for implementation in obstetric practice as an effective agent for fetal hypoxia.
In sports medicine, the use of Acyzol will increase performance and endurance in training processes by replenishing zinc in enzymatic systems, optimizing tissue respiration, and improving the oxygen-binding properties of blood.
Due to the presence of ionized zinc in the Acyzol dosage form, the drug can be used in the treatment of zinc-deficient conditions: Prasad’s disease, immunodeficiencies, alopecia, allergic dermatoses, prostate dysfunction, and delayed mental and physical development in children.
ICD codes
| ICD-10 code | Indication |
| D84.9 | Immunodeficiency, unspecified |
| E87.2 | Acidosis |
| F52.2 | Insufficiency of genital response (psychogenic impotence) |
| F89 | Unspecified disorder of psychological development |
| L20.8 | Other atopic dermatitis (neurodermatitis, eczema) |
| L23 | Allergic contact dermatitis |
| L24 | Irritant contact dermatitis |
| L28.0 | Lichen simplex chronicus (circumscribed neurodermatitis) |
| L63 | Alopecia areata |
| L64 | Androgenic alopecia |
| O36.3 | Signs of fetal intrauterine hypoxia requiring the provision of medical care to the mother |
| T58 | Toxic effect of carbon monoxide |
| Z73.0 | Burn-out |
| Z73.3 | Stress, not elsewhere classified (physical and mental strain) |
| ICD-11 code | Indication |
| 4A0Z | Unspecified primary immunodeficiencies |
| 5C73.Z | Acidosis, unspecified |
| 6A0Z | Neurodevelopmental disorders, unspecified |
| 9A06.70 | Atopic eczema of the eyelids |
| EA80.0 | Infantile atopic eczema |
| EA80.1 | Childhood atopic eczema |
| EA80.2 | Adult atopic eczema |
| EA80.Z | Atopic eczema, unspecified |
| EA83.00 | Lichen simplex of vulva |
| EA83.01 | Lichen simplex of male genital organs |
| EA83.02 | Lichen simplex of perianal area |
| EA83.0Z | Lichen simplex of unspecified location |
| EA85.20 | Atopic hand eczema |
| ED70.1 | Female pattern hair loss |
| ED70.2Z | Alopecia areata, unspecified |
| EK00.Z | Allergic contact dermatitis, unspecified |
| EK02.Z | Irritant contact dermatitis, unspecified |
| HA01.00 | Female sexual arousal dysfunction, lifelong, generalized |
| HA01.01 | Female sexual arousal dysfunction, lifelong, situational |
| HA01.02 | Female sexual arousal dysfunction, acquired, generalized |
| HA01.03 | Female sexual arousal dysfunction, acquired, situational |
| HA01.0Z | Female sexual arousal dysfunction, unspecified |
| HA01.10 | Male erectile dysfunction, lifelong, generalized |
| HA01.11 | Male erectile dysfunction, lifelong, situational |
| HA01.12 | Male erectile dysfunction, acquired, generalized |
| HA01.13 | Male erectile dysfunction, acquired, situational |
| HA01.Z | Sexual arousal dysfunctions, unspecified |
| JA86.2 | Maternal care for signs of intrauterine fetal hypoxia |
| NE61 | Toxic effect of poisonous substances, chiefly nonmedicinal, not elsewhere classified |
| QD85 | Burn-out |
| QE01 | Stress, not elsewhere classified |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Capsules
For prophylactic purposes, Acyzol is prescribed at a dose of 1 ml intramuscularly 20-30 minutes before or 1 capsule (120 mg) 30-40 minutes before entering a smoke-filled (gassed) area, when there is a high risk of CO inhalation, during work to eliminate the consequences of accidents and disasters accompanied by fires, or when extinguishing the fires themselves and rescuing victims.
The protective effect of Acyzol lasts for 1.5-2 hours when using the drug solution, and repeated administration is allowed 1 hour after the 1st administration. When using capsules, the protective effect lasts for 2-2.5 hours, and repeated administration of the drug is allowed after 1.5-2 hours.
Solution
For prophylactic purposes, 1 ml of Acyzol solution is administered intramuscularly when there is a threat of poisoning 20 – 30 minutes before the expected exposure to CO and thermal degradation products. Repeated administration is allowed 1 hour after the first administration.
As a therapeutic agent, Acyzol is recommended to be used as early as possible after poisoning, regardless of the severity of the lesion. The drug is administered at a dose of 1 ml intramuscularly immediately after the victim is removed from the fire area (gassed room). Subsequently, Acyzol is administered intramuscularly at 1 ml 2 – 4 times a day.
The maximum daily dose for an adult is 240 mg (4 ml).
The course of treatment averages 7 – 10 days.
Adverse Reactions
Acyzol does not exhibit side effects; in some cases, moderate pain at the injection site is possible.
Contraindications
- Hypersensitivity to the components of the drug Acyzol.
Special Precautions
The administration of Acyzol does not exclude the need for other therapeutic measures aimed at maintaining the vital functions of the body: oxygen therapy, infusion therapy.
Overdose
In case of an overdose of Acyzol, a metallic taste in the mouth, headache, and nausea are noted, which may occur during course treatment and disappear after discontinuation of the drug.
Storage Conditions
The drug should be stored in a place protected from light, at a temperature not exceeding 25°C (77°F).
Shelf Life
Shelf life – 2 years.
Dispensing Status
The drug is approved for use as an over-the-counter product.
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical DisclaimerBrand (or Active Substance), Marketing Authorisation Holder, Dosage Form
Capsules 120 mg: 1, 3, 10, 20, 30, 50, 100, 150, 500, or 1000 pcs.
Marketing Authorization Holder
Nizhpharm JSC (Russia)
Manufactured By
Makiz-Pharma, LLC (Russia)
Dosage Form
| Acyzol | Capsules 120 mg: 1, 3, 10, 20, 30, 50, 100, 150, 500, or 1000 pcs. |
Dosage Form, Packaging, and Composition
| Capsules | 1 caps. |
| Zinc bisvinylimidazole diacetate | 120 mg |
1 pcs. – blister packs (1) – cardboard packs.
1 pcs. – blister packs (50) – cardboard boxes.
1 pcs. – blister packs (100) – cardboard boxes.
3 pcs. – blister packs (1) – cardboard packs.
3 pcs. – blister packs (50) – cardboard boxes.
3 pcs. – blister packs (100) – cardboard boxes.
10 pcs. – blister packs (1) – cardboard packs.
10 pcs. – blister packs (3) – cardboard packs.
10 pcs. – blister packs (2) – cardboard packs.
10 pcs. – blister packs (50) – cardboard boxes.
10 pcs. – blister packs (100) – cardboard boxes.
30 pcs. – polymer jars (1) – cardboard packs.
50 pcs. – polymer jars (1) – cardboard packs.
Solution for intramuscular injection 60 mg/ml: 1 ml amp. 5, 10, 250, or 500 pcs.
Marketing Authorization Holder
Nizhpharm JSC (Russia)
Manufactured By
Russian Cardiological Research and Production Complex of the Ministry of Health of the Russian Federation – Branch of Experimental Production of Medical and Biological Preparations (Russia)
Dosage Form
| Acyzol | Solution for intramuscular injection 60 mg/ml: 1 ml amp. 5, 10, 250, or 500 pcs. |
Dosage Form, Packaging, and Composition
| Solution for intramuscular injection | 1 ml |
| Zinc bisvinylimidazole diacetate | 60 mg |
1 ml – ampoules (5) – blister packs (1) – cardboard packs.
1 ml – ampoules (5) – blister packs (2) – cardboard packs.
1 ml – ampoules (5) – blister packs (50) – cardboard boxes.
1 ml – ampoules (5) – blister packs (100) – cardboard boxes.
Actovegin pills 200mg, 50pcs
Noopept, pills 10mg, 50pcs
Kagocel pills 12mg, 30pcs
Ingavirin capsules 90mg, 10pcs
Cortexin, 10mg, 5ml, 10pcs
Belosalic, lotion solution for external use spray 100ml
Cerebrolysin, solution for injection 2ml ampoules 10pcs
Mildronate capsules 500mg, 90pcs
No-spa pills 40mg, 64pcs
Daivobet, ointment, 30g
Arbidol, capsules 100mg, 40pcs
Fenotropil pills 100mg, 60pcs 